The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Share News (ALM)

  • There is currently no data for ALM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allied Minds Interim Profit Falls Amid Finance Income Boost Year Prior

Thu, 26th Sep 2019 10:28

(Alliance News) - Allied Minds PLC on Thursday said its profit declined in the first half of 2019 after a very sharp cut in finance income.

Shares in Allied Minds were down 3.4% at 55.86 pence in London in morning trade.

The intellectual property commercialisation business reported a USD2.5 million pretax profit for the six months ended June 30, 42% below the USD4.3 million profit posted the year before.

While the firm made a USD33.9 million gain on investments held as fair value - compared to nothing the year before - this was more than offset by a sharp fall in net finance income to USD5.5 million from USD49.4 million.

Revenue dropped 29% to USD1.5 million from USD2.1 million after the deconsolidation of two of the company's portfolio companies in the second half of 2018.

Earlier in September, Allied agreed to sell its holding in portfolio company HawkEye 360 for USD65.6 million in cash.

Co-Chief Executives Joseph Pignato and Michael Turner said: "We have made good progress since our appointment to implement our revised strategy of focusing exclusively on supporting our existing portfolio companies and maximising monetisation opportunities at the right time, while reducing ongoing annualised HQ operating expenses.

"The strong funding rounds at HawkEye 360 and Federated Wireless, together with the significant technical and commercial progress throughout the technology portfolio, demonstrate the value and momentum of the portfolio.

"The announced sale of our HawkEye 360 shares is a major development. The sale provides an excellent return on invested capital, enables us to make a significant return of cash to shareholders, and strengthens our ability to continue to fund and support our existing technology portfolio."

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
24 Oct 2016 08:30

Allied Minds raises £5m from Neil Woodford for prostate cancer technology

(ShareCast News) - Star UK fund manager Neil Woodford has bought £5m of new shares in Allied Minds subsidiary Precision Biopsy. Woodford Investment Management, which is already a substantial shareholder in FTSE 250-listed Allied Minds purchased 0.95m preference shares in Precision Biopsy. Having de

Read more
29 Sep 2016 08:12

Allied Minds partners with GE Ventures to commercialise emerging tech

(ShareCast News) - FTSE 250 intellectual property company Allied Minds partnered with General Electric's venture capital subsidiary to commercialise next generation technologies. Allied Minds and GE Ventures agreed to invest in new and existing technologies from each of their innovation pipelines.

Read more
25 Aug 2016 08:05

Allied Minds losses increase but focus remains on future potential

(ShareCast News) - Allied Minds, the university and government technology commercialisation specialist, reported an increased loss, smaller revenue and flat value of its investment assets over the first half of the year. However, the company remains more firmly focused on investing in its various as

Read more
22 Aug 2016 07:07

Allied Minds secures debt funding and raises funds for drug programme

(ShareCast News) - Venture capital-style investor Allied Minds has arranged a one-year debt facility Silicon Valley Bank in the US, while its drug discovery subsidiary has raised funds for its leading project from institutional investors. Secured over certain group assets, the $20m one-year facility

Read more
1 Aug 2016 08:12

Allied Minds investment SciFluor gets nod from FDA

(ShareCast News) - Life science and technology investor Allied Minds announced on Monday that one of its key subsidiaries, SciFluor Life Sciences, has achieved the necessary scientific and regulatory milestones to enter clinical trials. The FTSE 250 company said SciFluor's Investigational New Drug a

Read more
13 Jun 2016 16:35

DIRECTOR DEALINGS: Allied Minds COO Marc Eichenberger Sells Shares

Read more
27 May 2016 15:30

FTSE 250 movers: Phoenix Group firms on AXA Wealth deal

(ShareCast News) - FTSE 250 was marginally firmer in late afternoon trade as UK traders wound down ahead of a long weekend, with few of today's in-the-news mid-cap stocks figuring among that index's top-10 risers. Shares in Phoenix Group Holdings were ahead as it agreed with AXA UK to buy AXA Wealth

Read more
25 May 2016 10:04

Allied Minds announces successful completion of feasibility programme

(ShareCast News) - Allied Minds' partnership with Bristol-Myers Squibb (BMS), Allied-Bristol Life Sciences, has successfully completed the drug candidate feasibility programme ABLS II and has approved up to $15m to fund further development of the lead optimisation programme. ABLS II is seeking to de

Read more
25 May 2016 07:08

Allied Minds Approves USD15 Million Funding For Allied-Bristol

Read more
19 May 2016 15:03

AGM, EGM Calendar - Week Ahead

Read more
13 May 2016 11:42

DIRECTOR DEALINGS: Allied Minds COO Sells 49,242 Shares

Read more
26 Apr 2016 09:30

WINNERS & LOSERS SUMMARY: Cobham Crushed On Weak Profit, Rights Issue

Read more
26 Apr 2016 08:47

Allied Minds secures £55m funding for up to ten new drugs

(ShareCast News) - Science and technology development and commercialisation company Allied Minds announced a fresh $80m (£55m) of investment commitments on Tuesday, received through its newly-formed subsidiary ABLS Capital. The FTSE 250 firm said the funding would allow up to ten potential lead opti

Read more
26 Apr 2016 06:50

Allied Minds Secures USD80 Million Commitments For Drug Development

Read more
25 Apr 2016 14:07

FTSE 250 movers: Ted Baker boosted as strike threat hits Wood Group

(ShareCast News) - The FTSE 250 remained in the black in afternoon trading on Monday, though some stocks were under the pump as crude and copper prices fell. Ted Baker was one of the leading risers, after analysts at Jefferies upgraded the stock to 'buy' from 'hold', though they did cut the price ta

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.